Abstract |
Immunoglobulin light chain ( AL) Amyloidosis is a condition whereby misfolded proteins generated by plasma cells deposit in tissues causing organ dysfunction. Chemotherapy and autologous stem cell transplant when eligible are standard treatment options. Several studies report long-term outcomes of patients post-transplant. However, there is a paucity of literature describing outcomes of relapsed patients post-transplant. We performed a retrospective study to assess outcomes and therapies employed upon relapse after transplant. Between 1996 and 2009, 410 patients received transplant at the Mayo Clinic as first-line therapy. Of those patients, 42 (10%) died within 3 months of transplant, 64 (16%) died without documented relapse, 158 (38%) were alive without documented progression, and 146 (36%) had documented progression. Those 146 patients are the subject of our study, and their median time to hematologic relapse/progression was 23.6 months (95%CI 18.3, 26.3 months). Their median overall survival and 5-yrs overall survival from post-transplant relapse/progression was 51.7 months (95%CI 34.1-62.3) and 39%, respectively. The most common first regimen for treatment after relapse was lenalidomide or thalidomide. In conclusion, our study indicates that patients with AL amyloidosis fare well post-transplant relapse/progression. Additionally, it provides a yardstick to design clinical trials to determine best treatment options.
|
Authors | Rahma Warsame, Soo Mee Bang, Shaji K Kumar, Morie A Gertz, Martha Q Lacy, Francis Buadi, David Dingli, Suzanne R Hayman, Prashant Kapoor, Robert A Kyle, Nelson Leung, John A Lust, Stephen J Russell, Thomas E Witzig, Steven R Zeldenrust, S Vincent Rajkumar, Angela Dispenzieri |
Journal | European journal of haematology
(Eur J Haematol)
Vol. 92
Issue 6
Pg. 485-90
(Jun 2014)
ISSN: 1600-0609 [Electronic] England |
PMID | 24502602
(Publication Type: Journal Article)
|
Copyright | © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- Immunoglobulin Light Chains
|
Topics |
- Adult
- Aged
- Amyloidosis
(metabolism, mortality, pathology, therapy)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Disease Progression
- Female
- Follow-Up Studies
- Hematopoietic Stem Cell Transplantation
- Humans
- Immunoglobulin Light Chains
(metabolism)
- Male
- Middle Aged
- Recurrence
- Transplantation, Autologous
- Treatment Outcome
|